Dyne Therapeutics Inc (NASDAQ: DYN) — Company Overview, News & Financial Data
Dyne Therapeutics advances muscle disease treatments using its FORCE™ platform, targeting conditions like Duchenne muscular dystrophy.
Dyne Therapeutics Inc
Dyne Therapeutics (NASDAQ:DYN) focuses on advancing modern muscle disease treatments with cutting-edge scientific discoveries aimed at improving lifecare for patients grappling with serious muscle disorders. Their ambitious projects include developing transformative therapies for conditions such as Duchenne muscular dystrophy, myotonic dystrophy, and facioscapulohumeral muscular dystrophy, employing innovative FORCE™ platform technology to precisely target and deliver therapeutic agents. Dyne's primary objective is to usher in a new era of effective treatments that can significantly enhance the quality of life for those affected by debilitating muscle diseases, demonstrating their commitment to pioneering advances in genetic medicine and therapy delivery.
Snapshot
Operations
Products and/or services of Dyne Therapeutics Inc
- Developing FORCE platform, a proprietary technology aimed at delivering oligonucleotides directly to muscle and heart tissues for treating genetic diseases.
- Advancing DYNE-101, a potential treatment targeting the mutation responsible for myotonic dystrophy type 1 (DM1), designed to improve muscle function.
- Working on DYNE-251 for Duchenne muscular dystrophy (DMD), focusing on skipping exon 51 to restore dystrophin protein production.
- Creating DYNE-301, targeting facioscapulohumeral muscular dystrophy (FSHD), aiming to reduce DUX4 expression, implicated in the disease's progression.
- Progressing with a preclinical program for centronuclear myopathies (CNM), to correct muscle strength and function by targeting underlying genetic mutations.
- Exploring additional therapeutic areas leveraging FORCE platform, extending potential treatments to other genetic muscle and cardiovascular conditions.
Dyne Therapeutics Inc executive team
- John G. CoxCEO, President & Director
- Erick J. LuceraCFO, Principal Financial Officer & Principal Accounting Officer and Treasurer
- Oxana BeskrovnayaChief Innovation Officer
- Johanna Friedl-NadererChief Commercial Officer
- Douglas KerrChief Medical Officer
- Axel WiestSenior VP and Head of Portfolio Strategy & Operations
- Rajesh ManchandaChief Technical Officer
- James P. BilottaChief Digital & Information Officer
- Alessandro MartuscelliChief Legal Officer
- Lucia CelonaChief Human Resource Officer
Latest news about Dyne Therapeutics Inc
Dyne gets priority review for DMD therapy
United StatesDyne Therapeutics seeks FDA accelerated approval for muscular dystrophy drug
United StatesDyne advances muscular dystrophy pipeline; BLA submission set for Q2
United StatesJapan grants orphan status to Dyne Therapeutics for muscle-wasting drug
United StatesDyne Therapeutics names rare disease veteran Vikram Karnani to board
United States
Key financials
Reported results for Dyne Therapeutics Inc, in USD.
- Market cap
- 3.2B
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -3.3
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -468.2M | -446.2M | |
| 0 | -343.9M | -317.4M | |
| 0 | -242.2M | -235.9M | |
| 0 | -171M | -165.2M |